Q2 EPS Forecast for Halozyme Therapeutics Reduced by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $1.06 per share for the quarter, down from their prior forecast of $1.07. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q3 2025 earnings at $1.14 EPS and Q4 2026 earnings at $1.78 EPS.

Several other equities analysts have also recently issued reports on the stock. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $60.89.

Halozyme Therapeutics Trading Down 0.0 %

Shares of HALO stock traded down $0.01 during mid-day trading on Friday, reaching $57.33. 1,143,541 shares of the stock traded hands, compared to its average volume of 1,301,450. The stock's fifty day simple moving average is $51.90 and its two-hundred day simple moving average is $54.42. Halozyme Therapeutics has a 1-year low of $34.36 and a 1-year high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market cap of $7.29 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Congress Asset Management Co. raised its position in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the period. Raymond James Financial Inc. bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth $21,838,000. Vanguard Group Inc. grew its holdings in Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after buying an additional 386,618 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock worth $13,756,000 after purchasing an additional 251,711 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its stake in Halozyme Therapeutics by 60.0% during the fourth quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company's stock valued at $31,112,000 after buying an additional 243,940 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.